{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:57:00Z","timestamp":1790873820588,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/npp.2017.194","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T07:00:26Z","timestamp":1503990026000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial"],"prefix":"10.1038","volume":"43","author":[{"given":"Jerome H","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeli","family":"Landeros-Weisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Coughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilian","family":"Mulqueen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot O","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgeni","family":"Jakubovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"BFnpp2017194_CR1","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/npp.2016.186","volume":"42","author":"CG Abdallah","year":"2016","unstructured":"Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C et al (2016). Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology 42: 1210\u20131219.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017194_CR2","first-page":"989","volume":"62","author":"RC Aitken","year":"1969","unstructured":"Aitken RC (1969). Measurement of feelings using visual analogue scales. Proc R Soc Med 62: 989.","journal-title":"Proc R Soc Med"},{"key":"BFnpp2017194_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0013164402062004005","volume":"62","author":"L Barnes","year":"2002","unstructured":"Barnes L, Harp D, Jung WS (2002). Reliability generalization of scores on the Spielberger state-trait anxiety inventory. Educ Psychol Meas 62: 603\u2013618.","journal-title":"Educ Psychol Meas"},{"key":"BFnpp2017194_CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351\u2013354.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","volume":"72","author":"MH Bloch","year":"2012","unstructured":"Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF et al (2012). Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry 72: 964\u2013970.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125\u2013136.","journal-title":"J Trauma Stress"},{"key":"BFnpp2017194_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/mp.2015.176","volume":"21","author":"F Carreno","year":"2015","unstructured":"Carreno F, Donegan J, Boley A, Shah A, DeGuzman M, Frazer A et al (2015). Activation of a ventral hippocampus\u2013medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol Psychiatry 21: 1298\u20131308.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2017194_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2466\/pr0.1986.59.2.827","volume":"59","author":"DF Cella","year":"1986","unstructured":"Cella DF, Perry SW (1986). Reliability and concurrent validity of three visual-analogue mood scales. Psychol Rep 59: 827\u2013833.","journal-title":"Psychol Rep"},{"key":"BFnpp2017194_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jclinepi.2006.07.015","volume":"60","author":"HM Davey","year":"2007","unstructured":"Davey HM, Barratt AL, Butow PN, Deeks JJ (2007). A one-item question with a Likert or Visual Analog Scale adequately measured current anxiety. J Clin Epidemiol 60: 356\u2013360.","journal-title":"J Clin Epidemiol"},{"key":"BFnpp2017194_CR10","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1523\/JNEUROSCI.4127-15.2016","volume":"36","author":"E Domi","year":"2016","unstructured":"Domi E, Uhrig S, Soverchia L, Spanagel R, Hansson AC, Barbier E et al (2016). Genetic deletion of neuronal PPAR\u03b3 enhances the emotional response to acute stress and exacerbates anxiety: an effect reversed by rescue of amygdala PPAR\u03b3 function. J Neurosci 36: 12611\u201312623.","journal-title":"J Neurosci"},{"key":"BFnpp2017194_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.biopsych.2013.12.014","volume":"76","author":"RJ Donahue","year":"2014","unstructured":"Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon WA (2014). Effects of striatal \u0394FosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry 76: 550\u2013558.","journal-title":"Biol Psychiatry"},{"issue":"4","key":"BFnpp2017194_CR12","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaac.2017.01.006","volume":"56","author":"Jennifer B. Dwyer","year":"2017","unstructured":"Dwyer JB, Beyer C, Wilkinson ST, Ostroff RB, Qayyum Z, Bloch MH (2017). Ketamine as a treatment for adolescent depression: a case report. J Am Acad Child Adolescent Psychiatry 56: 352\u2013354..","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"key":"BFnpp2017194_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","volume":"71","author":"A Feder","year":"2014","unstructured":"Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S et al (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71: 681\u2013688.","journal-title":"JAMA Psychiatry"},{"key":"BFnpp2017194_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.pnpbp.2010.02.028","volume":"34","author":"MC Freitas-Ferrari","year":"2010","unstructured":"Freitas-Ferrari MC, Hallak JE, Trzesniak C, Santos Filho A, Machado-de-Sousa JP, Chagas MHN et al (2010). Neuroimaging in social anxiety disorder: a systematic review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 34: 565\u2013580.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"BFnpp2017194_CR15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1177\/0269881117705089","volume":"31","author":"Paul Glue","year":"2017","unstructured":"Glue P, Medlicott NJ, Harland S, Neehoff S, Anderson-Fahey B, Le Nedelec M et al (2017). Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol 0269881117705089. doi:10.1177\/0269881117705089; e-pub ahead of print.","journal-title":"Journal of Psychopharmacology"},{"key":"BFnpp2017194_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/npp.2016.210","volume":"42","author":"TD Gould","year":"2017","unstructured":"Gould TD, Zanos P, Zarate CA (2017). Ketamine mechanism of action: separating the wheat from the chaff. Neuropsychopharmacology 42: 368\u2013369.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017194_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpp2017194_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1017\/S0033291798007879","volume":"29","author":"RG Heimberg","year":"1999","unstructured":"Heimberg RG, Horner K, Juster H, Safren S, Brown E, Schneier F et al (1999). Psychometric properties of the Liebowitz social anxiety scale. Psychol Med 29: 199\u2013212.","journal-title":"Psychol Med"},{"key":"BFnpp2017194_CR19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.4088\/JCP.14m09049","volume":"75","author":"DF Ionescu","year":"2014","unstructured":"Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Voort JLV et al (2014). Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J clin psychiatry 75: 932\u2013938.","journal-title":"J clin psychiatry"},{"key":"BFnpp2017194_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","volume":"179","author":"MP Johnson","year":"2005","unstructured":"Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE et al (2005). Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model (s). Psychopharmacology (Berl) 179: 271\u2013283.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFnpp2017194_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4088\/JCP.13m08922","volume":"76","author":"JM Kelly","year":"2014","unstructured":"Kelly JM, Jakubovski E, Bloch MH (2014). Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial. J clin psychiatry 76: 267\u2013278.","journal-title":"J clin psychiatry"},{"key":"BFnpp2017194_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1034\/j.1600-0447.108.s417.2.x","volume":"108","author":"R Kessler","year":"2003","unstructured":"Kessler R (2003). The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatr Scand 108: 19\u201327.","journal-title":"Acta Psychiatr Scand"},{"key":"BFnpp2017194_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Chiu WT, Demler O, Walters EE (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch gen psychiatr 62: 617\u2013627.","journal-title":"Arch gen psychiatr"},{"key":"BFnpp2017194_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291716000064","volume":"46","author":"T Kishimoto","year":"2016","unstructured":"Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M et al (2016). Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46: 1459\u20131472.","journal-title":"Psychol Med"},{"key":"BFnpp2017194_CR25","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","volume":"73","author":"JH Krystal","year":"2013","unstructured":"Krystal JH, Sanacora G, Duman RS (2013). Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73: 1133\u20131141.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR26","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","volume":"72","author":"G Laje","year":"2012","unstructured":"Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N et al (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72: e27.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000414022","volume":"22","author":"MR Liebowitz","year":"1987","unstructured":"Liebowitz MR (1987). Social phobia. Mod Prob Pharmacopsychiatry 22: 141\u2013173.","journal-title":"Mod Prob Pharmacopsychiatry"},{"key":"BFnpp2017194_CR28","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4088\/JCP.v64n0708","volume":"64","author":"MR Liebowitz","year":"2003","unstructured":"Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H et al (2003). Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64: 785\u2013792.","journal-title":"J Clin Psychiatry"},{"key":"BFnpp2017194_CR29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/da.22546","volume":"33","author":"MR Liebowitz","year":"2016","unstructured":"Liebowitz MR, Hanover R, Draine A, Lemming R, Careri J, Monti L (2016). Effect of as\u2010needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depress Anxiety 33: 1081\u20131089.","journal-title":"Depress Anxiety"},{"key":"BFnpp2017194_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2165\/00019053-200018010-00003","volume":"18","author":"JD Lipsitz","year":"2000","unstructured":"Lipsitz JD, Schneier FR (2000). Social phobia. Pharmacoeconomics 18: 23\u201332.","journal-title":"Pharmacoeconomics"},{"key":"BFnpp2017194_CR31","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/npp.2016.202","volume":"42","author":"R-J Liu","year":"2016","unstructured":"Liu R-J, Duman C, Kato T, Hare B, Lopresto D, Bang E et al (2016). GLYX-13 produces rapid antidepressant responses with key synaptic and behavioral effects distinct from ketamine. Neuropsychopharmacology 42: 1231\u20131242.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017194_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11920-007-0063-1","volume":"9","author":"S Maeng","year":"2007","unstructured":"Maeng S, Zarate CA Jr (2007). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr psychiatry rep 9: 467\u2013474.","journal-title":"Curr psychiatry rep"},{"key":"BFnpp2017194_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/npp.2017.19","volume":"42","author":"JC McGowan","year":"2017","unstructured":"McGowan JC, LaGamma CT, Lim SC, Tsitsiklis M, Neria Y, Brachman RA et al (2017). Prophylactic ketamine attenuates learned fear. Neuropsychopharmacology 42: 1577\u20131589.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017194_CR34","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0887-6185(02)00134-2","volume":"16","author":"DS Mennin","year":"2002","unstructured":"Mennin DS, Fresco DM, Heimberg RG, Schneier FR, Davies SO, Liebowitz MR (2002). Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J Anxiety Disord 16: 661\u2013673.","journal-title":"J Anxiety Disord"},{"key":"BFnpp2017194_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"M Milak","year":"2015","unstructured":"Milak M, Proper C, Mulhern S, Parter A, Kegeles L, Ogden R et al (2015). A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 21: 320\u2013327.","journal-title":"Mol Psychiatry"},{"key":"BFnpp2017194_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.biopsych.2016.07.005","volume":"80","author":"JW Murrough","year":"2016","unstructured":"Murrough JW (2016). Ketamine for depression: an update. Biol Psychiatry 80: 416\u2013418.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR37","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM et al (2013a). Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170: 1134\u20131142.","journal-title":"Am J Psychiatry"},{"key":"BFnpp2017194_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M et al (2013b). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250\u2013256.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-pharmtox-011613-135950","volume":"54","author":"MJ Niciu","year":"2014","unstructured":"Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS (2014). Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 54: 119\u2013139.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFnpp2017194_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1037\/a0038402","volume":"83","author":"TS Peris","year":"2015","unstructured":"Peris TS, Compton SN, Kendall PC, Birmaher B, Sherrill J, March J et al (2015). Trajectories of change in youth anxiety during cognitive\u2013behavior therapy. J Consult Clin Psychol 83: 239.","journal-title":"J Consult Clin Psychol"},{"key":"BFnpp2017194_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00001756-200502080-00024","volume":"16","author":"KL Phan","year":"2005","unstructured":"Phan KL, Fitzgerald DA, Cortese BM, Seraji-Bozorgzad N, Tancer ME, Moore GJ (2005). Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. Neuroreport 16: 183\u2013186.","journal-title":"Neuroreport"},{"key":"BFnpp2017194_CR42","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.pnpbp.2007.11.023","volume":"32","author":"MH Pollack","year":"2008","unstructured":"Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF (2008). High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Prog Neuropsychopharmacol Biol Psychiatry 32: 739\u2013743.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFnpp2017194_CR43","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/WNR.0b013e328273bcb0","volume":"18","author":"L Ribeiro","year":"2007","unstructured":"Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P et al (2007). The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. Neuroreport 18: 1291.","journal-title":"Neuroreport"},{"key":"BFnpp2017194_CR44","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"CI Rodriguez","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D et al (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 38: 2475\u20132483.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017194_CR45","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1001\/jama.2010.608","volume":"303","author":"P Roy-Byrne","year":"2010","unstructured":"Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ et al (2010). Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. Jama 303: 1921\u20131928.","journal-title":"Jama"},{"key":"BFnpp2017194_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","volume":"65","author":"G Salvadore","year":"2009","unstructured":"Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA et al (2009). Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65: 289\u2013295.","journal-title":"Biol Psychiatry"},{"key":"BFnpp2017194_CR47","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/npp.2016.193","volume":"42","author":"G Sanacora","year":"2016","unstructured":"Sanacora G, Heimer H, Hartman D, Mathew S, Frye M, Nemeroff C et al (2016). Balancing the promise and risks of ketamine treatment for mood disorders. Neuropsychopharmacology 42: 1179\u20131181.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpp2017194_CR48","doi-asserted-by":"crossref","unstructured":"Spielberger CD . Manual for the State-Trait Anxiety Inventory STAI (form Y)(\u2018self-evaluation questionnaire\u2019). Mind Garden: Palo Alto, CA, 1983.","DOI":"10.1037\/t06496-000"},{"key":"BFnpp2017194_CR49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jpsychires.2015.03.020","volume":"65","author":"JH Taylor","year":"2015","unstructured":"Taylor JH, Jakubovski E, Bloch MH (2015). Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial. J Psychiatr Res 65: 154\u2013165.","journal-title":"J Psychiatr Res"},{"key":"BFnpp2017194_CR50","unstructured":"Taylor JH, Lebowitz ER, Silverman WK . Anxiety Disorders. In A. Martin, M.H. Bloch, F.R. Volkmar (eds.), Lewis\u2019s child and adolescent psychiatry: A comprehensive textbook. 5th edition. Wolters Kluwer: Philadelphia, PA, 2017a, pp. 509\u2013518.."},{"key":"BFnpp2017194_CR51","doi-asserted-by":"crossref","unstructured":"Taylor JH, Lebowitz ER, Jakubovski E, Coughlin CG, Silverman WK, Bloch MH (2017b). Monotherapy insufficient in severe anxiety? Predictors and moderators in the Child\/Adolescent Anxiety Multimodal Study. J Clin Child Adolesc Psychol in press.","DOI":"10.1080\/15374416.2017.1371028"},{"issue":"6","key":"BFnpp2017194_CR52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/ijpo.12165","volume":"12","author":"J. H. Taylor","year":"2016","unstructured":"Taylor JH, Xu Y, Li F, Shaw M, Dziura J, Caprio S et al (2016). Psychosocial predictors and moderators of weight management programme outcomes in ethnically diverse obese youth. Pediatr Obes. doi:10.1111\/ijpo.12165.","journal-title":"Pediatric Obesity"},{"key":"BFnpp2017194_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","volume":"191","author":"GW Valentine","year":"2011","unstructured":"Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B et al (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1 H]-MRS. Psychiatry Res Neuroimag 191: 122\u2013127.","journal-title":"Psychiatry Res Neuroimag"},{"key":"BFnpp2017194_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0091-3057(01)00698-0","volume":"71","author":"DL Walker","year":"2002","unstructured":"Walker DL, Davis M (2002). The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 71: 379\u2013392.","journal-title":"Pharmacol Biochem Behav"},{"key":"BFnpp2017194_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1477-7525-8-57","volume":"8","author":"VS Williams","year":"2010","unstructured":"Williams VS, Morlock RJ, Feltner D (2010). Psychometric evaluation of a visual analog scale for the assessment of anxiety. Health qual life outcomes 8: 57.","journal-title":"Health qual life outcomes"},{"key":"BFnpp2017194_CR56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856\u2013864.","journal-title":"Arch Gen Psychiatry"},{"key":"BFnpp2017194_CR57","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","volume":"150","author":"M Zimmerman","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K (2013). Severity classification on the Hamilton depression rating scale. J Affect Disord 150: 384\u2013388.","journal-title":"J Affect Disord"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/npp2017194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017194","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/npp.2017.194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/npp2017194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:58:20Z","timestamp":1684439900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npp2017194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFnpp2017194"],"URL":"https:\/\/doi.org\/10.1038\/npp.2017.194","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.729805125.793537113","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"assertion":[{"value":"29 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}